Drug maker, Lupin said that it has entered into a strategic collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar developed for Cetuximab.
Cetuximab has received approval from the Drug Controller General of India (DCGI) for treating head and neck cancer, particularly Squamous Cell Carcinoma of the head and neck (SCCHN), the company said in a BSE filing.
Cetuximab is available as a 100mg vial.